Regulatory flexibility can make continuous improvement possible.
Mark Schenerman
Advertisement
Mark Schenerman is the vice president of analytical biochemistry at MedImmune
Articles by Mark Schenerman
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Advertisement
Latest Updated Articles
Quality by Design for Biotechnology Products—Part 3January 1st 2010
Quality by Design for Biotechnology Products—Part 2December 1st 2009
Quality by Design for Biotechnology Products—Part 1November 1st 2009
Advertisement
Advertisement